15
Benefits of Obesity Medications
Cardiovascular Disease
• Semaglutide:
▶ Demonstrated a relative risk reduction of 20% and an absolute
risk reduction of 1.5% over an average follow-up period of 39.8
months in patients with established cardiovascular disease.
• Tirzepatide:
▶ Demonstrated an improvement in health status among patients
with heart failure with preserved ejection f raction and obesity.
Obstructive Sleep Apnea
• In patients with moderate to severe obstructive sleep apnea
and obesity, tirzepatide reduced the apnea-hypopnea index
and hypoxic burden while also improving sleep-related patient-
reported outcomes.
Renal Insufficiency
• Semaglutide signif icantly reduces the risk of clinically relevant
kidney outcomes and mortality f rom cardiovascular causes
in patients with type 2 diabetes mellitus (T2DM) and chronic
kidney disease, including those with albuminuria and reduced
estimated glomerular f iltration rate (eGFR). Liraglutide reduces
both the incidence and progression of diabetic kidney disease in
comparison to a placebo.
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
• In patients with MASH and stage 2 or 3 f ibrosis, treatment
with once-weekly semaglutide led to increased resolution of
steatohepatitis without worsening of f ibrosis.
• In patients with MASLD and moderate-to-severe f ibrosis,
tirzepatide at maintenance doses of 10 or 15 mg over a 52-week
period exhibited signif icantly greater eff icacy in achieving
resolution compared to placebo, without any observed
deterioration in f ibrosis.
Osteoarthritis
• Semaglutide, assessed at 68 weeks, resulted in a signif icantly
greater reduction in pain related to knee osteoarthritis compared
to placebo. In patients with knee osteoarthritis and overweight
or obesity, liraglutide administered after an 8-week dietary
intervention did not reduce knee pain compared to placebo at 52
weeks. However, it did result in a signif icant weight loss.
